EM574, an erythromycin derivative, improves delayed gastric emptying of semi-solid meals in conscious dogs.
The gastroprokinetic effects of de(N-methyl)-N-isopropyl-8, 9-anhydroerythromycin A 6,9-hemiacetal (EM574), a non-peptide motilin receptor agonist, were investigated in conscious dogs in a normal state and with experimentally-induced gastroparesis. Gastric emptying of semi-solid meals was assessed indirectly from acetaminophen absorption with simultaneous recording of gastric antral motility. In the normal state, post-prandial intraduodenal administration of EM574 (0.03 mg/kg) [corrected] stimulated antral motility and significantly enhanced gastric emptying as potently as did intravenous porcine motilin (0.003 mg/kg/h). Intraduodenal cisapride at 1 mg/kg denal cisapride at 1 mg/kg elicited antral contractions and tended to accelerate gastric emptying but at 3 mg/kg, gastric emptying was not enhanced despite a further increase in the motor index. In dogs with gastroparesis induced by intraduodenal oleic acid or intravenous dopamine, EM574 (0.03 mg/kg) increased antral motility and reversed the delayed gastric emptying completely. Cisapride (1 mg/kg) partially ameliorated the impaired emptying under these conditions. In atropinized dogs, no acceleration of gastric emptying by EM574 was observed. These results indicate that EM574 potently accelerates gastric emptying of caloric meals in dogs in a normal state and with experimentally-induced gastroparesis, and also suggest that the effect is mediated through stimulation of a cholinergic neural pathway.
Sato
F
F
Pharmacology Laboratories II, Takeda Chemical Industries, Ltd., 2-17-85, Juso-Honmachi, Yodogawa-ku, Osaka, Japan.
Marui
S
S
Inatomi
N
N
Itoh
Z
Z
Omura
S
S
D000818:Animals; D001285:Atropine / Q000494:pharmacology; D020117:Cisapride / Q000494:pharmacology; D004285:Dogs; D004917:Erythromycin / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000494:pharmacology; D005746:Gastric Emptying / Q000187:drug effects*; D005765:Gastrointestinal Agents / Q000009:adverse effects / Q000494:pharmacology*; D018589:Gastroparesis / Q000139:chemically induced / Q000503:physiopathology*; D008297:Male; D009037:Motilin / Q000494:pharmacology; D018727:Muscarinic Antagonists / Q000494:pharmacology; D011985:Receptors, Serotonin / Q000378:metabolism; D044422:Receptors, Serotonin, 5-HT4; D017366:Serotonin Receptor Agonists / Q000494:pharmacology
D005765:Gastrointestinal Agents; D018727:Muscarinic Antagonists; D011985:Receptors, Serotonin; D017366:Serotonin Receptor Agonists; C090116:Idremcinal; D044422:Receptors, Serotonin, 5-HT4; D009037:Motilin; D004917:Erythromycin; D001285:Atropine; D020117:Cisapride